This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy
by Zacks Equity Research
Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
by Zacks Equity Research
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
by Zacks Equity Research
Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B
by Zacks Equity Research
Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.
Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
by Zacks Equity Research
TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
by Zacks Equity Research
Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
Dr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal third-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in core businesses in North America and Europe.
Kodiak Sciences Inc. (KOD) Up 43.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data
by Zacks Equity Research
EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.
Kodiak (KOD) Beats Q3 Earnings, Provides Pipeline Updates
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
by Zacks Equity Research
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
Should You Buy Kodiak Sciences (KOD) Ahead of Earnings?
by Zacks Equity Research
Kodiak Sciences (KOD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
3 Biotech Stocks Poised to Beat Q2 Earnings Estimates
by Ekta Bagri
We look at a few biotech companies, LEGN, KOD, GRTX, which are poised to beat second-quarter earnings estimates.
Ligand (LGND) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Eli Lilly's (LLY) second-quarter sales.
Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More
by Zacks Equity Research
Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.
Kodiak (KOD) Down as Late-Stage DME Studies Fail
by Zacks Equity Research
Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.
Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
by Zacks Equity Research
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.